Latest Ratios: P/E Ratio -11.8x · EV/EBITDA N/A · ROE N/A. (2020–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $39M | $49M | $38M | $6M | $127M | $151M | — |
| Enterprise Value | $39M | $49M | $47M | $11M | $153M | $155M | — |
| P/E Ratio → | -11.85 | — | — | — | — | — | — |
| P/S Ratio | 28.48 | 36.06 | 59.38 | 5.62 | 109.85 | 138.40 | — |
| P/B Ratio | — | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 36.05 | 72.75 | 10.57 | 132.38 | 142.24 | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | -37.0% | -37.0% | -43.7% | -12.6% | -31.2% | -10.4% | 25.8% |
| Operating Margin | -711.3% | -711.3% | -1493.8% | -671.2% | -669.1% | -248.3% | -355.8% |
| Net Profit Margin | -206.1% | -206.1% | -1575.3% | -3308.5% | -2641.0% | -269.4% | -342.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — |
| ROA | -95.3% | -95.3% | -483.5% | -3856.0% | -2803.9% | -485.7% | -860.5% |
| ROIC | — | — | — | — | — | — | — |
| ROCE | — | — | — | — | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -40.79 | -40.79 | -67.89 | -3068.27 | -75.46 | -14.05 | — |
Net cash position: cash ($585000) exceeds total debt ($570000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.43 | 0.43 | 0.19 | 0.03 | 0.01 | 0.18 | 0.19 |
| Quick Ratio | 0.43 | 0.43 | 0.19 | 0.03 | 0.01 | 0.18 | 0.19 |
| Cash Ratio | 0.23 | 0.23 | 0.16 | 0.00 | 0.01 | 0.15 | 0.05 |
| Asset Turnover | — | 0.63 | 0.17 | 2.20 | 0.89 | 1.24 | 2.51 |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 132.95 | 120.91 | 54.21 | 6.01 | 30.67 | 86.54 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.5% | 0.0% | 69.9% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.5% | 0.0% | 69.9% | 0.0% | — |
| Shares Outstanding | — | $45M | $28M | $7M | $12M | $15M | $15M |
Imminent liquidity and solvency
Based on current market data, ONMD trades at a price-to-sales ratio of 26.44, a valuation that appears disconnected from its negative gross margins and suggests investors are pricing in a high-growth AI narrative rather than the company's current reality of project-based, low-margin clinical data brokerage services.
The elevated P/S multiple relative to the broader healthcare information services sector implies an aggressive growth expectation that the company's current financial trajectory has yet to validate. Investors should monitor whether this premium is sustainable given the lack of recurring revenue and the persistent inability to achieve positive operating margins.
As reported in recent financial statements, the company's gross margin of -37.01% highlights a fundamental cost-revenue mismatch, indicating that the direct expenses associated with data curation and partner network maintenance currently exceed the pricing power the firm can command within the competitive life sciences R&D market.
The persistent negative gross margin suggests that the company has not yet achieved the necessary data reuse ratio to amortize its curation costs effectively. This structural weakness, combined with an operating margin of -711.33%, indicates that the firm's administrative and R&D overhead remains vastly decoupled from its current revenue-generating capacity.
According to quarterly filings, the company's asset turnover ratio of 0.05 in 2026Q1 underscores a significant underutilization of the balance sheet, suggesting that the firm's current infrastructure is not yet generating sufficient throughput to justify its existing capital base or support a path toward operational self-sufficiency.
The extreme volatility in days sales outstanding, which has fluctuated significantly across recent periods, points to a reliance on lumpy, project-based contracts that complicate cash flow forecasting. This lack of operational rhythm makes it difficult for the company to optimize its working capital cycle or reduce its dependence on external financing.
Based on the most recent quarterly data, the company maintains a current ratio of 0.27 and a cash balance of only $585,000, which indicates a severe liquidity constraint that leaves the firm with minimal buffer to absorb operational shocks or fund ongoing research and development initiatives.
The current liquidity position appears insufficient to cover short-term obligations, suggesting that the company may face an imminent need for dilutive capital raises to remain a going concern. Investors should monitor the firm's ability to secure non-dilutive funding or achieve a rapid improvement in cash conversion to mitigate these solvency risks.
The market's focus on the 111% year-over-year revenue growth rate is a commonly misapplied metric for this business model, as it obscures the underlying lack of recurring revenue and the high variable costs that prevent the company from achieving a sustainable, scalable economic profile in the near term.
Analysts should prioritize the data reuse ratio and gross margin trends over headline revenue growth to better assess the company's true earning power. Relying on top-line growth in a project-based, negative-margin business model risks ignoring the fundamental reality that the firm's current operational structure is not yet value-accretive.
Includes 30+ ratios · 6 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ONMD stock.
OneMedNet Corporation's current P/E ratio is -11.8x. This places it at the 50th percentile of its historical range.
Based on historical data, OneMedNet Corporation is trading at a P/E of -11.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
OneMedNet Corporation has -37.0% gross margin and -711.3% operating margin.